Skip to main content
Premium Trial:

Request an Annual Quote

10x Genomics Inks Sequencing Partnerships With Qiagen, Illumina

NEW YORK (GenomeWeb) – 10x Genomics has announced two new sequencing partnerships with Qiagen and Illumina.

Yesterday, 10x said that it is partnering with Qiagen to co-develop and co-market next-generation sequencing and single-cell biology analysis workflows and informatics solutions.

Under the terms of the agreement, Qiagen will optimize its sample technologies — including its MagAttract HMW DNA kit — for use on 10x's GemCode platform and Chromium product suite for single-cell analysis.

They also plan to develop solutions that support complete single-cell biology workflows by combining 10x's GemCode technology with Qiagen's single-cell biology portfolio and QIAseq NGS solutions, and to investigate the implementation of GemCode with Qiagen's GeneReader NGS system.

"We welcome the opportunity to partner with Qiagen, with their comprehensive offerings for genomic analysis, ranging from sample preparation technologies to bioinformatics solutions for the interpretation and analysis of genomic data," said 10x CEO Serge Saxonov in a statement. "Access to long-range sequence information is becoming the standard for obtaining the most comprehensive understanding of disease, and we expect this collaboration to allow our respective customers to gain valuable insights that have previously not been possible."

The companies will co-market the 10x Chromium products and the Qiagen sample handling and prep technologies, and plan to collaborate to develop a comprehensive portfolio of products to improve sample preparation, sequencing, and single-cell biology, 10x said.

"This partnership will further the potential of each of our product lines while providing significant new capabilities to NGS researchers," added Qiagen CEO Peer Schatz in the statement.

Separately, 10x and Illumina said today that they are partnering to co-market Illumina's sequencing systems and 10x's linked-read sequencing products. 10x’s microfluidics-based molecular barcoding long read solutions, built on the GemCode platform, can be used with Illumina sequencers to give researchers a wider range of sequencing applications to choose from, the company said.

"We are excited to establish this ecosystem and to have 10x Genomics as a partner," Illumina Chief Commercial Officer Christian Henry said in a statement. "The GemCode technology provides HiSeq X, HiSeq, NextSeq, and MiSeq sequencing users a plug-and-play upgrade to their existing systems, giving them access to a broad range of critical information, and at a much lower cost and a higher quality than other long-read sequencing systems on the market." 

This is the second such partnership Illumina has announced in recent months. The company also signed a co-marketing agreement with ag-bio firm NRGene in January, and expects to announce more ecosystem partnerships in 2016.

Financial terms of the deals were not disclosed.

The Scan

Steps for Quick Review

The US Food and Drug Administration is preparing for the quick review of drugs and vaccines for the Omicron variant, according to the Wall Street Journal.

Moving Away From Using Term 'Race'

A new analysis finds that geneticists are using the term "race" in their papers less than in years past, as Science reports.

Point of the Program

The Guardian writes that some scientists have called the design of a UK newborn sequencing program into question.

Science Papers Present Multi-Omic Analysis of Lung Cells, Regulation of Cardiomyocyte Proliferation

In Science this week: a multi-omic analysis of lung cells focuses on RIT1-regulated pathways, and more.